You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
Researcher Amanda Paulovich will develop multiple-reaction monitoring mass spectrometry assays and apply them to samples from cancer patients in the program.
The researchers found that using proteomic data in addition to mRNA data to predict gene function improves upon traditional transcriptomic approaches.
According to NCI, the MOUs will facilitate the coordination of research and sharing of data and tests for use by scientists and oncologists around the world.
Under the collaboration, University of Victoria researchers will add 2,000 new multiple reaction-monitoring mass spec assays to the CPTAC Assay Portal.
Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
The CPTAC study integrated proteomic and genomic data from 77 breast cancer tumors with the aim of identifying potential biomarkers and therapeutic targets.
Among other aims, the five-year effort hopes to use genomic and proteomic data to better understand patient drug response and the development of resistance.
The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.
The organizations will use proteomics to characterize tumors and compare these proteomic characterizations to other forms of data including genomic profiles.
A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.
According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.